TALDO1 and renal pelvis/ureter urothelial carcinoma: Regarding TALDO1, previous studies have highlighted its overexpression in head and neck carcinomas, gastric cancer, colorectal cancer, upper tract urothelial carcinoma, ovarian cancer, and hepatocellular carcinoma metastases [44,45,46,47,48,49].